$0.72 EPS Expected for Masimo Co. (MASI) This Quarter

Equities research analysts expect that Masimo Co. (NASDAQ:MASI) will post $0.72 earnings per share (EPS) for the current quarter, according to Zacks. Four analysts have issued estimates for Masimo’s earnings. The lowest EPS estimate is $0.71 and the highest is $0.72. Masimo also reported earnings per share of $0.72 in the same quarter last year. The company is scheduled to announce its next earnings report on Tuesday, February 26th.

On average, analysts expect that Masimo will report full-year earnings of $2.92 per share for the current year. For the next financial year, analysts expect that the business will post earnings of $3.01 per share, with EPS estimates ranging from $2.97 to $3.05. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Masimo.

Masimo (NASDAQ:MASI) last posted its earnings results on Wednesday, October 31st. The medical equipment provider reported $0.71 EPS for the quarter, topping the consensus estimate of $0.69 by $0.02. Masimo had a net margin of 17.08% and a return on equity of 20.29%. The firm had revenue of $210.58 million during the quarter, compared to analysts’ expectations of $207.62 million. During the same quarter in the prior year, the firm earned $0.56 EPS. Masimo’s quarterly revenue was up 8.9% on a year-over-year basis.

Several analysts recently commented on the stock. Zacks Investment Research lowered shares of Masimo from a “buy” rating to a “hold” rating in a research note on Monday, December 3rd. Piper Jaffray Companies upped their price target on shares of Masimo to $120.00 and gave the company a “neutral” rating in a research report on Thursday, November 1st. BidaskClub lowered shares of Masimo from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 3rd. Stifel Nicolaus upped their price objective on shares of Masimo from $112.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, October 2nd. Finally, UBS Group initiated coverage on shares of Masimo in a research note on Tuesday, November 27th. They issued a “buy” rating and a $137.00 price objective on the stock. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $119.00.

In related news, COO Anand Sampath sold 30,000 shares of the company’s stock in a transaction on Wednesday, November 28th. The shares were sold at an average price of $110.00, for a total transaction of $3,300,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Sanford Fitch sold 2,000 shares of the company’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $113.14, for a total transaction of $226,280.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,000 shares of company stock worth $3,748,080. 12.60% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Moody Aldrich Partners LLC bought a new stake in shares of Masimo during the 2nd quarter worth $2,919,000. American International Group Inc. boosted its holdings in shares of Masimo by 1.8% during the 3rd quarter. American International Group Inc. now owns 97,787 shares of the medical equipment provider’s stock worth $12,178,000 after buying an additional 1,699 shares during the period. Matarin Capital Management LLC bought a new stake in shares of Masimo during the 3rd quarter worth $11,202,000. Russell Investments Group Ltd. boosted its holdings in shares of Masimo by 5.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 31,916 shares of the medical equipment provider’s stock worth $3,973,000 after buying an additional 1,560 shares during the period. Finally, Thrivent Financial for Lutherans boosted its holdings in shares of Masimo by 5.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 11,489 shares of the medical equipment provider’s stock worth $1,431,000 after buying an additional 634 shares during the period. 82.05% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ:MASI traded down $1.13 during trading on Wednesday, reaching $112.25. The company had a trading volume of 2,631 shares, compared to its average volume of 460,712. Masimo has a twelve month low of $80.69 and a twelve month high of $126.89. The firm has a market cap of $5.94 billion, a P/E ratio of 45.65, a P/E/G ratio of 2.36 and a beta of 0.99.

Masimo Company Profile

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Story: Terms to Better Understand Call Options

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit